ALK

ALK inhibitors cover anaplastic lymphoma kinase and activin receptor-like kinases, two unrelated groups named ALK. Anaplastic lymphoma kinase was identified in 1994 as a tyrosine kinase fused to nucleophosmin (NPM) in a non-Hodgkin lymphoma. In 2007 a fusion with echinoderm microtubule-associated protein-like 4 (EML4) was found in non-small-cell lung cancer. Crizotinib, TAE684, brigatinib and entrectinib inhibit anaplastic lymphoma kinase, and entrectinib also blocks tropomyosin receptor kinases (Trk). Activin receptor-like kinases (ALKs) are type I receptors for transforming growth factor beta (TGF-β) family ligands. A 83-01 inhibits ALK4, ALK5 and ALK7 and blocks Smad signaling by TGF-β. Vactosertib also targets ALK4 and ALK5, while LDN193189 and DMH-1 inhibit the bone morphogenetic protein receptor ALK2.

Items 101-125 of 150

  • ALK/ROS1-IN-1
    Cat. No.
    A34527

    ALK/ROS1-IN-1

    ALK/ROS1-IN-1 is a potent and selective dual inhibitor targeting ALK and ROS1, demonstrating IC50 values of 0.174 μM for ALK and 0.530 μM for ROS1. This compound is particularly effective against crizotinib-resistant variants, making it valuable for research applications focusing on cancer therapeutics and drug resistance mechanisms. Its ability to modulate these key oncogenic pathways makes it a significant tool for studying the therapeutic potential in various cancer models.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PROTAC EML4-ALK Degrader-2
    Cat. No.
    A34528

    PROTAC EML4-ALK Degrader-2

    PROTAC EML4-ALK Degrader-2 is an advanced degrader specifically targeting the EML4-ALK fusion protein. With an IC50 of 1.6 nM, it exhibits potent selective inhibitory activity against ALK while maintaining selectivity over IGF1R, INSR, FLT3, and FGFR2. This compound demonstrates significant anti-cancer effects in both in vitro and in vivo models and is particularly relevant for research applications involving non-small cell lung cancer (NSCLC), as well as liver and cervical cancers.

    Out of stock

    All 3 sizes
  • ALK2-IN-5
    Cat. No.
    A34529

    ALK2-IN-5

    ALK2-IN-5 is a pyrazolopyrimidine compound that selectively inhibits ALK2 activity, as well as FGFR activity. This compound demonstrates significant potential in research applications related to disorders influenced by dysregulated ALK2 and FGFR, including various cancer types. Its ability to modulate these key pathways makes it a valuable tool for investigating the molecular mechanisms underlying ALK2 and FGFR-related pathologies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • ALK-IN-23
    Cat. No.
    A34530

    ALK-IN-23

    ALK-IN-23 is a selective ALK inhibitor exhibiting IC50 values of 1.6 nM, 0.71 nM, and 1.3 nM against ALKWT, ALKL1196M, and ALKG1202R respectively. It effectively arrests the cell cycle in the G2 phase and promotes apoptosis in cancer cells. Additionally, ALK-IN-23 demonstrates the ability to inhibit cancer cell migration and colony formation in vitro, while revealing promising antitumor efficacy in H2228 xenograft models with low toxicity. This reagent is suitable for studies focused on ALK-related pathways and cancer therapeutics.

    Out of stock

    All 3 sizes
  • SIAIS117
    Cat. No.
    A34531

    SIAIS117

    SIAIS117 is a potent Brigatinib-PROTAC degrader that targets the ALK protein, specifically effective against the ALK G1202R point mutation. By utilizing a VHL-1 conjugation, SIAIS117 exhibits significant capability to induce protein degradation, leading to inhibited growth of SR and H2228 cancer cell lines. This compound holds potential for applications in anti-proliferative research, particularly in small cell lung cancer contexts.

    Out of stock

    All 3 sizes
  • Con B-1
    Cat. No.
    A34532

    Con B-1

    Con B-1 is a potent and selective inhibitor of anaplastic lymphoma kinase (ALK), exhibiting low toxicity towards normal cells. This compound effectively modulates ALK activity, making it valuable for research into ALK-driven cancers. It is suitable for use in studies related to targeted therapies and evaluation of cancer cell proliferation and survival pathways.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (E)-Belizatinib
    Cat. No.
    A34533

    (E)-Belizatinib

    Synonyms: (E)-TSR-011

    (E)-Belizatinib is a potent and selective anaplastic lymphoma kinase (ALK) inhibitor, exhibiting an enzymatic IC50 of 0.005 μM and a cellular IC50 of 0.048 μM. Demonstrating over 61-fold selectivity for ALK over JAK2, SRC, and IGF1R, (E)-Belizatinib possesses favorable pharmacokinetic properties in both rats and dogs. This compound is valuable for research focused on ALK-driven cancers, offering significant potential for therapeutic development in this area.

    Out of stock

    All 3 sizes
  • ALK5-IN-79
    Cat. No.
    A34534

    ALK5-IN-79

    ALK5-IN-79 is a selective ALK5 inhibitor that interferes with TGF-β1/SMAD signaling pathways, exhibiting significant anticancer activity. This compound reduces extracellular matrix production and collagen deposition, making it pertinent for studies focused on fibrosis and cancer progression. ALK5-IN-79 demonstrates favorable pharmacokinetic properties and good in vivo tolerance, supporting its potential as a therapeutic agent in various research applications.

    25 mg
    $1,530.00
    50 mg
    $2,115.00
    All 3 sizes
  • KRCA-0713
    Cat. No.
    A34535

    KRCA-0713

    KRCA-0713 is a potent inhibitor of anaplastic lymphoma kinase (ALK), demonstrating robust anti-ALK activity in both enzyme and cell-based assays. This compound effectively suppresses ALK-driven tumor growth, as evidenced by studies conducted in H3122 xenograft models. KRCA-0713 serves as a valuable tool for researchers investigating ALK-related oncogenesis and therapeutic responses in cancer treatment.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • ALK5-IN-26
    Cat. No.
    A34536

    ALK5-IN-26

    ALK5-IN-26 is a potent inhibitor of Activin receptor-like kinase 5 (ALK5), exhibiting an IC50 value of ≤10 nM. This compound is valuable for research applications investigating the role of ALK5 in cancer progression and related pathways. Its high specificity and efficacy make it a useful tool for elucidating the mechanistic underpinnings of tumor biology.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • WZH-15-125
    Cat. No.
    A34537

    WZH-15-125

    WZH-15-125 is a potent anaplastic lymphoma kinase (ALK) inhibitor, showing significant activity against compound ALK mutations that contribute to drug resistance. With an IC50 of 101.7 nM, it effectively targets the G1202R/L1196M mutation, which demonstrates resistance to Lorlatinib. WZH-15-125 serves as a valuable ligand for PROTAC synthesis, specifically for the development of PROTAC WZH-17-002. This compound is particularly relevant for research in non-small cell lung cancer, offering new avenues for therapeutic exploration.

    Out of stock

    All 3 sizes
  • ALK-IN-13
    Cat. No.
    A34538

    ALK-IN-13

    ALK-IN-13 is a selective inhibitor of anaplastic lymphoma kinase (ALK), targeting key pathways involved in oncogenesis. This compound exhibits potent anti-tumor activity, making it valuable for research focused on ALK-driven cancers, including non-small cell lung cancer. Its mechanism of action allows for detailed studies of ALK signaling and the development of targeted therapeutic strategies.

    5 mg
    $795.00
    All 1 sizes
  • PROTAC ALK degrader-1
    Cat. No.
    A34539

    PROTAC ALK degrader-1

    PROTAC ALK degrader-1 is a potent ALK degrader utilizing the proteolysis-targeting chimera (PROTAC) mechanism, exhibiting a DC50 of 26 nM in H3122 EML4-ALK cells. This compound enables selective degradation of ALK, thereby offering potential therapeutic benefits for ALK-driven cancers. Additionally, PROTAC ALK degrader-1 serves as a precursor for synthesizing PROTAC ALK degrader-2, which may possess enhanced bioavailability for further research applications.

    Out of stock

    All 3 sizes
  • F6524-1593
    Cat. No.
    A34540

    F6524-1593

    F6524-1593 is an ALK inhibitor that demonstrates significant inhibitory activity against A549 and HepG-2 cell lines, with IC50 values of 161.1 μM and 91.03 μM, respectively. This compound is valuable for research involving ALK-related malignancies, including non-small cell lung cancer, lymphoma, and neuroblastoma. Its ability to selectively target ALK makes it a potential tool for understanding and developing treatments for these cancers.

    Out of stock

    All 3 sizes
  • PROTAC ALK degrader-5
    Cat. No.
    A34541

    PROTAC ALK degrader-5

    PROTAC ALK degrader-5 is a targeted degrader composed of a small molecule that selectively degrades anaplastic lymphoma kinase (ALK). It demonstrates potent inhibitory activity against EML4-ALK and NPM-ALK, with IC50 values of 27.4 nM and 116.5 nM, respectively. This compound exhibits significant anti-proliferative effects against ALK-driven cancer cell lines, including H3122 and Karpas 299, and effectively inhibits ALK and STAT3 phosphorylation. PROTAC ALK degrader-5 is a valuable tool for investigating ALK-driven malignancies, particularly in the context of human non-small cell lung cancer and anaplastic large cell lymphoma research.

    Out of stock

    All 3 sizes
  • ALK-IN-21
    Cat. No.
    A34542

    ALK-IN-21

    ALK-IN-21 is a potent inhibitor of the anaplastic lymphoma kinase (ALK), specifically targeting the ALKG1202R mutation. It demonstrates exceptional enzymatic inhibitory potency, with IC50 values of 4.59 nM for ALKWT, 2.07 nM for ALKL1196M, and 5.95 nM for ALKG1202R. This compound effectively inhibits the proliferation of ALK-positive Karpas299 and H2228 cell lines, exhibiting IC50 values of 0.07 μM. ALK-IN-21 is essential for research on anaplastic large cell lymphoma and related ALK-driven malignancies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • TD-004
    Cat. No.
    A34543

    TD-004

    TD-004 is a highly effective ALK PROTAC degrader, demonstrating potent anti-ALK inhibitory activity with an IC50 of 0.11 µM. This compound selectively hampers the proliferation of ALK-positive cancer cell lines, SU-DHL-1 and H3122, with IC50 values of 0.058 µM and 0.28 µM, respectively. TD-004 induces the degradation of ALK fusion proteins, including NPM-ALK and EML4-ALK, through the recruitment of the VHL E3 ligase and the proteasome pathway. Its significant tumor growth inhibition and favorable safety profile in vivo make TD-004 a valuable tool for researching anaplastic large cell lymphoma and non-small cell lung cancer.

    Out of stock

    All 3 sizes
  • ALK5-IN-29
    Cat. No.
    A34544

    ALK5-IN-29

    ALK5-IN-29 is a selective inhibitor of activin receptor-like kinase 5 (ALK5), demonstrating potent inhibitory activity with an IC50 value of ≤10 nM. This compound has been shown to effectively inhibit tumor growth, making it a valuable tool for research in proliferative diseases, including cancer. Its specificity for ALK5 allows for targeted studies examining the role of this kinase in various biological processes and therapeutic interventions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • ALK ligand-Linker Conjugate 1
    Cat. No.
    A34545

    ALK ligand-Linker Conjugate 1

    ALK ligand-Linker Conjugate 1 is designed to facilitate the synthesis of PROTAC ALK degrader-4, targeting the Anaplastic Lymphoma Kinase (ALK) pathway. This compound serves as a vital component in developing protein-targeting chimeras for therapeutic applications in cancer research. Its efficient linkage promotes effective degradation of ALK, making it a valuable tool for studies focused on modulating oncogenic signaling pathways.

    Out of stock

    All 3 sizes
  • Dirozalkib
    Cat. No.
    A34546

    Dirozalkib

    Dirozalkib is a potent ALK inhibitor with an IC50 value of 0.9 nM. It demonstrates significant anti-proliferative activity in cancer cell lines, including NCI-H3122, Karpas-299, and NCI-H2228, with IC50 values of 130.4, 0.71, and 15.11 nM, respectively. Dirozalkib also possesses favorable pharmacokinetic properties, with a bioavailability of 30% to 50%, making it a valuable tool for research in cancer therapeutics.

    Out of stock

    All 3 sizes
  • TL13-110
    Cat. No.
    A34547

    TL13-110

    TL13-110 is a selective ALK inhibitor that demonstrates an IC50 of 0.34 nM. This compound serves as a negative control for TL13-112 while exhibiting minimal interaction with cellular ALK degradation. TL13-110 is suitable for research applications focused on the exploration of ALK-related pathways and therapeutic strategies in oncology.

    5 mg
    $800.00
    All 1 sizes
  • CDD-2789
    Cat. No.
    A34548

    CDD-2789

    CDD-2789 is a highly selective small-molecule inhibitor of Activin receptor type 1 (ALK2, or ACVR1), which targets the SMAD1/5 signaling pathway. By effectively blocking ALK2/ALK1-mediated phosphorylation events triggered by BMP and activin A, CDD-2789 demonstrates a potent inhibitory effect with an IC50 of 0.54 µM in the NanoBRET cellular model. This compound is invaluable for research into ALK2-associated diseases, such as diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

    5 mg
    $150.00
    10 mg
    $240.00
    All 5 sizes
  • KRCA-0377
    Cat. No.
    A34550

    KRCA-0377

    KRCA-0377 is an orally active inhibitor of anaplastic lymphoma kinase (ALK) that demonstrates potent activity with an IC50 of 0.001 μM against the wild-type enzyme, and ≤0.01 μM for mutant forms. This compound exhibits significant cytotoxic effects against cancer cells and effectively inhibits tumor growth in xenograft mouse models. KRCA-0377 is suitable for research applications focusing on ALK-positive non-small-cell lung cancer.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • ALK/EGFR-IN-2
    Cat. No.
    A34551

    ALK/EGFR-IN-2

    ALK/EGFR-IN-2 is a potent dual inhibitor targeting anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). This compound induces apoptosis and causes G0/G1 cell cycle arrest in cancer cells, contributing to its efficacy. It demonstrates significant inhibition of cell proliferation in H1975, PC9, and Baf3-EML4-ALK cancer cell lines, with IC50 values of 0.0034, 0.0065, and 0.0018 μM, respectively. ALK/EGFR-IN-2 is valuable for research focused on cancer therapeutics and pathway analysis.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • ALK-IN-12
    Cat. No.
    A34552

    ALK-IN-12

    ALK-IN-12 is a potent and orally bioavailable inhibitor of Anaplastic Lymphoma Kinase (ALK), exhibiting an IC50 of 0.18 nM. In addition to its action on ALK, it also inhibits Insulin-like Growth Factor 1 Receptor (IGF1R) and Insulin Receptor (InsR), with IC50 values of 20.3 nM and 90.6 nM, respectively. The compound demonstrates significant antitumor activity, making it a valuable tool for cancer research focused on ALK-driven malignancies and cellular signaling pathways involving IGF1R and InsR.

    5 mg
    $795.00
    All 1 sizes

Items 101-125 of 150

Added to your cart

View Cart Checkout

    Loading...